TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy - Result

TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

M. Eriksen
C. W. Yde
L. B. Ahlborn
Qvortrup, Camilla
Lassen, Ulrik Niels
M. Højgaard
I. Spanggaard
K. S. Rohrberg

Original language	English
Journal	European Journal of Cancer
Volume	174
Issue number	S1
Pages (from-to)	S118
ISSN	0959-8049
DOIs	https://doi.org/10.1016/S0959-8049(22)01115-7
Publication status	Published - 2022

ID: 340536994